Famous Harvard researcher analytic signal-regulated

From the Institute for Regenerative Medicine at Massachusetts General Hospital, Harvard University, etc. The researchers found leukemia, a key signaling mechanism was proposed before the AKT / FOXOs unknown new features, introduce new treatments for leukemia patients of different genotypes ideas. AKT is also known as protein kinase B (PKB), is a relative molecular mass of 60 000 serine / threonine kinase, the protein associated with a number of malignancies, partial inhibition of FOXO by tumor suppressor involved in tumorigenesis. In this article, the researchers discovered a new type of irreversible effects in acute myeloid leukemia AML AKT / FOXOs http://www.cusabio.com/Recombinant-Protein/Recombinant-Drosophila-melanogaster--Forkhead-box-protein-Ofoxo-partial-895378.html for further study AML mechanisms and cancer signaling pathways proposed new insights.

AML Acute myeloid leukemia is a primary abnormal blood cells in the bone marrow rapidly growing invasive cancer, the incidence increases as people age. The most common symptoms of AML is weight loss, fatigue, fever, night sweats and anorexia, can diffuse infiltration of the disease to other parts of the body such as the lymph nodes, liver and spleen.

In this article, the researchers analyzed a number of AML patients, regardless of their genotype is found, four percent of the AML patients in FOXOs are activated, which is contrary to previous findings. By further experiments, researchers have found that with AML indeed other cancers, which requires a low expression of AKT, and high expression of FOXO. And this is also related to the activity of FOXO JNK / c-JUN signaling pathways related to these experimental data suggest that the AKT / FOXO, as well as the important role of JNK / c-JUN signaling pathway in terms of maintaining the differentiation barriers, such barriers can be used Targeted inhibition of leukemia, which will propose new ideas to treat leukemia patients of different genotypes, and also help scientists in-depth analysis of signaling pathways in leukemia.

In addition, Scadden doctoral research group also recently on Natureiotechnology magazine, reported that stem cells and other new method for separating blood cells and tumor cells. They peripheral blood mononuclear cells (MCs) into pulsed electric field, the mononuclear cells can be selectively removed, and some small lymphocytes can be preserved, these small lymphocytes remaining in function, and can be centrifuged They will be separated from the dead cells.

The researchers first MCs and tumor cells were mixed and then the mixture was placed in an electric field, the tumor cells can be selectively removed. Moreover, the a portable electric field after implantation of tumor cells into immunodeficient mice, no tumor. Finally, studies of peripheral blood stem cells will be placed in the electric field studies, found that the method can increase the CD34- positive / CD38- negative stem cells while maintaining their functions. This method is compared with the use of antibody was purified cell separation technique, the system requires less reagent, and therefore the lower the cost. For those who need a transplant patients with hematologic malignancies in terms of the method is the best way to get the separation and purification of stem cells.